<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Med</journal-id><journal-id journal-id-type="pmc">Open Med</journal-id><journal-title-group><journal-title>Open Medicine</journal-title></journal-title-group><issn pub-type="epub">1911-2092</issn><publisher><publisher-name>Open Medicine Publications, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21688755</article-id><article-id pub-id-type="pmc">3090111</article-id><article-id pub-id-type="publisher-id">OpenMed-03-e184-195</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review</article-title></title-group><contrib-group><contrib id="contrib1" contrib-type="author"><name><surname>Wilson</surname><given-names>Michael G</given-names></name><bio><p><bold>Michael G Wilson</bold> is a doctoral candidate in the Health Research Methodology Program, McMaster University, Hamilton, Ontario, and associate scientist, knowledge transfer and exchange, Ontario HIV Treatment Network (OHTN), Toronto, Ontario, Canada.</p></bio></contrib><contrib id="contrib2" contrib-type="author"><name><surname>Dickie</surname><given-names>Melisa</given-names></name><degrees>MHSc</degrees><bio><p><bold>Melisa Dickie</bold>, MHSc, is manager, health publications, Canadian AIDS Treatment Information Exchange, Toronto.</p></bio></contrib><contrib id="contrib3" contrib-type="author"><name><surname>Cooper</surname><given-names>Curtis L</given-names></name><degrees>MD</degrees><bio><p><bold>Curtis L Cooper</bold>, MD, is associate professor of medicine, University of Ottawa, the Ottawa Hospital Division of Infectious Disease, Ottawa, Ontario.</p></bio></contrib><contrib id="contrib4" contrib-type="author"><name><surname>Carvalhal</surname><given-names>Adriana</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><bio><p><bold>Adriana Carvalhal</bold>, MD, PhD, is assistant professor at the department of psychiatry and behavioural neuroscience, McMaster University, Hamilton.</p></bio></contrib><contrib id="contrib5" contrib-type="author"><name><surname>Bacon</surname><given-names>Jean</given-names></name><degrees>BSc</degrees><bio><p><bold>Jean Bacon</bold>, BSc, is at the OHTN, Toronto.</p></bio></contrib><contrib id="contrib6" contrib-type="author"><name><surname>Rourke</surname><given-names>Sean B</given-names></name><degrees>PhD</degrees><bio><p><bold>Sean B Rourke</bold>, PhD, is at the OHTN, the Centre for Research on Inner City Health and Li Ka Shing Knowledge Institute, St. Michael&#x02019;s Hospital, Toronto, and is associate professor in the department of psychiatry, University of Toronto, Toronto.</p></bio></contrib></contrib-group><author-notes><corresp>Correspondence: Michael G. Wilson, Ontario HIV Treatment Network, 1300 Yonge St., Suite 308, Toronto ON  M4T 1X3; <email>wilsom2@mcmaster.ca</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>6</day><month>10</month><year>2009</year></pub-date><volume>3</volume><issue>4</issue><fpage>e184</fpage><lpage>e195</lpage><history><date date-type="received"><day>5</day><month>2</month><year>2008</year></date><date date-type="rev-request"><day>29</day><month>3</month><year>2008</year></date><date date-type="rev-recd"><day>8</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2008</year></date></history><permissions><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/2.5/ca/"><license-p>Open Medicine applies the Creative Commons Attribution Share Alike License, which means that anyone is able to freely copy, download, reprint, reuse, distribute, display or perform this work and that authors retain copyright of their work. Any derivative use of this work must be distributed only under a license identical to this one and must be attributed to the authors. Any of these conditions can be waived with permission from the copyright holder. These conditions do not negate or supersede Fair Use laws in any country.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://www.openmedicine.ca/article/view/214/271">http://www.openmedicine.ca/article/view/214/271</self-uri><abstract><sec><title>Background</title><p>Providing care for people who are co-infected with both HIV and hepatitis C virus (HCV) is becoming increasingly complex and requires integrated prevention, screening, support and programming efforts. We undertook a scoping review to provide a summary of the existing evidence base and to identify and assess the quality of treatment guidelines and systematic reviews related to 3 domains of interest: treatment; epidemiology; and care, support, programming and prevention.</p></sec><sec sec-type="methods"><title>Methods</title><p>We searched 7 databases, hand-searched 8 journals and contacted key informants to identify relevant literature. We included all primary research (including systematic reviews and meta-analyses) or treatment guidelines that assessed pegylated interferon and ribavirin for HCV or highly active antiretroviral therapy for HIV treatment, or both. In the epidemiology domain, we included all primary research (including systematic reviews and meta-analyses). Studies that included only people with hemophilia and those conducted in developing countries were excluded. In the care, support, programming and prevention domain, we included all studies and reports that focused on co-infection. Two reviewers independently applied coding criteria and assessed the quality of the treatment guidelines and systematic reviews using the Appraisal of Guidelines Research and Evaluation and A MeaSurement Tool to Assess Reviews instruments. </p></sec><sec><title>Results</title><p>Our search strategy yielded 1633 unique references. Of these, 227 references met the final inclusion criteria: 114 addressed treatment, 52 epidemiology and 79 care, support, programming or prevention. The references included 9 treatment guidelines: 4 were assessed as &#x0201c;strongly recommend,&#x0201d; 3 as &#x0201c;recommend (with provisos or alterations)&#x0201d; and 1 as &#x0201c;would not recommend&#x0201d; (1 could not be located). Of 10 systematic reviews that were located, 7 were assessed as being high quality, 2 as medium quality and 1 as low quality.</p></sec><sec><title>Conclusion</title><p>This quality-assessed inventory of treatment guidelines and systematic reviews can be used by physicians and service providers to rapidly locate research about HIV&#x02013;HCV co-infection. However, many treatment guidelines and reviews often indicate that treatment of current injection drug users and/or people with mental health issues should proceed on a &#x0201c;case-by-case basis.&#x0201d; Therefore, much of the evidence (particularly in the treatment literature) is limited in its scope and applicability to important populations that are vulnerable to HIV or HCV infection or co-infection.</p></sec></abstract></article-meta></front><body><p>The availability and accessibility of highly active antiretroviral therapy (HAART) in Canada has extended the length and improved the quality of life of people with HIV.<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref> As a result, important co-morbidities are now emerging among people living with HIV. This has increased the complexity of their health and health care needs.<xref ref-type="bibr" rid="ref3">3</xref>-<xref ref-type="bibr" rid="ref5">5</xref> The hepatitis C virus (HCV) commonly affects people with HIV and is a leading cause of death among people with HIV.<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref6">6</xref></p><p>Currently in Canada, it is estimated that a large proportion (18%) of people with HIV are co-infected with HCV.<xref ref-type="bibr" rid="ref7">7</xref> The strongest predictor or risk factor of co-infection is a history of injection drug use (IDU), with co-infection rates estimated to range from 50% to 92%.<xref ref-type="bibr" rid="ref7">7</xref>-<xref ref-type="bibr" rid="ref20">20</xref> As a result, the populations affected most severely by co-infection are those in which IDU is most prevalent, such as current and former prisoners and Aboriginal people (First Nations, Inuit and M&#x000e9;tis).<xref ref-type="bibr" rid="ref16">16</xref> For instance, 2 separate studies in Ontario and Quebec prisons found that the prevalence of HCV among inmates infected with HIV was 68% and 64.8%, respectively.<xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></p><p>Combination HCV therapy with pegylated interferon and ribavirin is available for some people with HIV&#x02013;HCV co-infection; however, the likelihood of treatment success (sustained virological response, defined as plasma free of HCV 6 months after completion of therapy) is diminished in people with HIV&#x02013;HCV co-infection (genotype 1: &#x002dc;15%&#x02013;30% , genotype 2, 3: &#x002dc;55%&#x02013;60%)<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref> compared with people infected with HCV alone (genotype 1: &#x002dc;40%&#x02013;50%, genotype 2, 3: &#x002dc;70%&#x02013;90%).<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref></p><p>The design and implementation of programs to deliver effective medical care for patients with HIV&#x02013;HCV co-infection should take into account the differences in the psychosocial and medical status between some individuals.<xref ref-type="bibr" rid="ref27">27</xref> Research has consistently identified substantially lower quality of life and cognitive function and a higher prevalence of mental illness among patients co-infected with HIV and HCV.<xref ref-type="bibr" rid="ref28">28</xref> Current guidelines state that treatment for HCV infection can be started for patients co-infected with HIV who currently use illicit drugs or have mental illness.<xref ref-type="bibr" rid="ref29">29</xref> However, active drug use and mental illness and their associated morbidities, such as homelessness and lack of social support, represent an important barrier to accessing treatment and to drug adherence. In addition, the presence of active depression before HCV treatment with interferon-based therapies is highly predictive of the development of clinically important depression during therapy, which is associated with significantly low virological response and low adherence rates.<xref ref-type="bibr" rid="ref30">30</xref> The treatment of mental illness in co-infected individuals before the administration of HCV treatment represents a critical step in the successful care and support of co-infected patients.</p><p>In response to these complex treatment issues and the need to support care and community service providers who work with people who are co-infected, we undertook a scoping review (i.e., a rapid but rigorous assessment of the literature; see <xref ref-type="fig" rid="box1">Box 1</xref> for a description of scoping reviews) to provide a summary of the existing evidence base and an inventory of relevant systematic reviews and treatment guidelines that are currently available. Our specific objectives were to identify and assess the quality of systematic reviews and treatment guidelines about treatment, care, support, programming and prevention, as well as about the epidemiologic profile of HIV and HCV co-infection. We describe the sources and types of available evidence, identify areas where systematic reviews could be completed and highlight where additional primary research is needed.</p><fig id="box1" position="float"><label>Box 1</label><caption><p>Scoping reviews</p></caption><graphic xlink:href="OpenMed-03-e184-g001"/></fig><sec sec-type="methods"><title>Methods</title><sec><title>Literature search</title><p>We used 3 strategies &#x02014; database searches, journal hand-searching and key contacts &#x02014; to identify published and unpublished literature. Our search strategies were designed to provide a balance between a rapid assessment of the literature and a comprehensive survey of the literature about HIV&#x02013;HCV co-infection. First, we searched 7 databases (MEDLINE, PubMed, Cochrane Library, PsycINFO, AIDSearch, Canadian HIV/AIDS Policy &#x00026; Law Review, and Google Scholar) from 1996 to January 2007 using combinations of search terms developed through consultation with a librarian at the University of Toronto (see <xref ref-type="app" rid="appendix1">Appendix 1</xref> for a full list of search terms). Given that our focus was on Canadian and North American content and that we wanted to perform a rapid assessment of the literature, we prioritized a relatively small subset of databases. Therefore, we selected MEDLINE and PubMed to capture treatment-related information, PsycINFO to capture literature related to mental health, AIDSearch to capture additional HIV-relevant literature, and Canadian HIV/AIDS Policy &#x00026; Law Review to identify any policy-related documents that may not be indexed in the health sciences literature, and Google Scholar to identify any additional grey literature. We then hand-searched 8 journals (<italic>Canadian Medical Association Journal, AIDS Care, AIDS Policy and Law, Annals of Internal Medicine, Canadian Journal of Gastroenterology, HIV Medicine, Journal of Acquired Immune Deficiency Syndromes</italic> and <italic>New England Journal of Medicine</italic>). These 8 journals were recommended by 2 members of our team (CLC and AC) who deal extensively with co-infection issues. For each journal, we reviewed all issues from January 2000 to January 2007 and identified all systematic reviews, treatment guidelines and primary research that addressed treatment, epidemiology, and/or care, support, programming and prevention for people co-infected with HIV and HCV. We also contacted relevant researchers from 5 Canadian universities (McGill University, University of Alberta, University of British Columbia, McMaster University and the University of Toronto) and 4 organizations in Canada in the field of HIV and HCV (University Health Network, Centre for Addictions and Mental Health, Insite &#x02013; Supervised Injection Site and Vancouver Coastal Health Authority) and asked them to identify any published and unpublished works that would be relevant to our review.</p></sec><sec><title>Article review and selection</title><p>We used an iterative and reflexive approach to develop and apply inclusion and coding criteria to the search results. First, from the electronic database search results, 2 pairs of independent reviewers (MGW and a research assistant; MD and a research assistant) reviewed the first 200 titles and abstracts retrieved and assigned each a code based on whether the publication addressed a question about HIV&#x02013;HCV co-infection, whether it studied or discussed a Canadian population or an international population, the study design and the subject area addressed. We then met as a team and created additional codes for specific study populations and subject areas of interest. Next, 2 pairs of independent reviewers (MGW and a research assistant; MD and a research assistant) reviewed all of the titles and abstracts identified in our initial searches and excluded those not related to HIV&#x02013;HCV co-infection.</p><p>We then collectively developed inclusion criteria for 3 domains (treatment; epidemiology; and care, support, programming and prevention) and 2 pairs of independent reviewers (MGW and a research assistant; MD and a research assistant) applied the inclusion criteria to all remaining titles and abstracts. In the treatment domain, we included all primary research (including systematic reviews and meta-analyses) and treatment guidelines that assessed pegylated interferon and ribavirin for HCV (current standard of care) or HAART for HIV treatment, or both. In the epidemiology domain, we included primary research (including systematic reviews and meta-analyses). For both the treatment and epidemiology domains, we excluded studies that included only people with hemophilia and those conducted in developing countries. Because of the lack of literature on care, support, programming and prevention, for this domain we included all studies and reports that focused on co-infection. </p><p>Next, we collectively refined the coding framework to include 24 characteristics across 4 categories &#x02014; study design, study population, country or region of study and scope of study. Using the full text of each article, 2 of us (MGW and MD) independently assigned the new codes to each of the included references (Boxes <xref ref-type="fig" rid="box2">2</xref>&#x02013;<xref ref-type="fig" rid="box4">4</xref>). Disagreements were resolved through discussion until consensus was reached. </p><p>Last, 2 pairs of independent raters assessed the quality of each of the included systematic reviews and treatment guidelines (disagreements were resolved through discussion until consensus was reached). For systematic reviews, 2 independent raters (MGW and a research coordinator) applied the AMSTAR (A MeaSurement Tool to Assess Reviews) instrument, which has strong face and content validity and has been shown to be the strongest quality-assessment tool for systematic reviews.<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref> The AMSTAR instrument produces a quality score between 0 and 11, with ranges representing low (scores of 0&#x02013;3), medium (4&#x02013;7) and high (8&#x02013;11) quality.<xref ref-type="bibr" rid="ref35">35</xref> For treatment guidelines, 2 independent raters (MGW and AC) applied the AGREE (Appraisal of Guidelines Research and Evaluation) instrument, which is designed to be used by a wide range of professionals, demonstrates strong reliability and is the only internationally tested instrument.<xref ref-type="bibr" rid="ref36">36</xref> AGREE consists of 23 items (4-point Likert scales) across 6 domains, which are used to produce 3 possible conclusions: &#x0201c;strongly recommend,&#x0201d; &#x0201c;recommend (with provisos or alterations)&#x0201d; or &#x0201c;would not recommend.&#x0201d;<xref ref-type="bibr" rid="ref37">37</xref></p><fig id="box2" position="float"><label>Box 2</label><caption><p>Key findings: treatment for HIV&#x02013;HCV co-infection</p></caption><graphic xlink:href="OpenMed-03-e184-g002"/></fig><fig id="box3" position="float"><label>Box 3</label><caption><p>Key findings: epidemiology of HIV&#x02013;HCV co-infection</p></caption><graphic xlink:href="OpenMed-03-e184-g003"/></fig><fig id="box4" position="float"><label>Box 4</label><caption><p>Key findings: care, support, programming and prevention for HIV&#x02013;HCV co-infection</p></caption><graphic xlink:href="OpenMed-03-e184-g004"/></fig></sec></sec><sec><title>Results</title><p>Our search strategy yielded 1633 articles (2598 before duplicate removal). Of these, 227 met the final inclusion criteria (<xref ref-type="fig" rid="figure1">Fig. 1</xref>). The full bibliography of included articles is available at <ext-link ext-link-type="uri" xlink:href="http://www.ohtn.on.ca/Pages/Knowledge-Exchange/HIV-HCV-Scoping-Review.aspx">http://www.ohtn.on.ca/Pages/Knowledge-Exchange/HIV-HCV-Scoping-Review.aspx</ext-link>. Agreement for the 2 sets of reviewers (calculated only at the inclusion-assessment stage; <xref ref-type="fig" rid="figure1">Fig. 1</xref>) was fair, with Kappa statistics of 0.377 and 0.249.</p><p>Of the 227 articles, 9 were treatment guidelines and 10 were systematic reviews (<xref ref-type="fig" rid="table1">Table 1</xref>). Of the 9 treatment guidelines, 4 were &#x0201c;strongly recommended,&#x0201d;<xref ref-type="bibr" rid="ref38">38</xref>-<xref ref-type="bibr" rid="ref41">41</xref> 3 were &#x0201c;recommended (with provisos or alterations)&#x0201d;<xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref> and 1 was classified as &#x0201c;would not recommend&#x0201d;;<xref ref-type="bibr" rid="ref44">44</xref> 1 guideline could not be assessed because it could not be located.<xref ref-type="bibr" rid="ref45">45</xref> Of the 10 included systematic reviews, 3 addressed topics related to treatment,<xref ref-type="bibr" rid="ref46">46</xref>-<xref ref-type="bibr" rid="ref48">48</xref> 3 focused on epidemiology,<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref50">50</xref> 4 focused on care or support<xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref51">51</xref>-<xref ref-type="bibr" rid="ref53">53</xref> and 4 focused on prevention<xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref52">52</xref>,<xref ref-type="bibr" rid="ref54">54</xref>,<xref ref-type="bibr" rid="ref55">55</xref> (5 reviews addressed more than 1 domain). Through our quality assessments of the included systematic reviews we found 7 to be of high quality,<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref51">51</xref>-<xref ref-type="bibr" rid="ref55">55</xref> with only 2 rated as medium quality<xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref50">50</xref> and 1 as low quality.<xref ref-type="bibr" rid="ref47">47</xref></p><p>We found 114 publications or reports in the treatment domain, 52 in the epidemiology domain and 79 in the care, support, programming and prevention domain (Boxes <xref ref-type="fig" rid="box2">2</xref>&#x02013;<xref ref-type="fig" rid="box4">4</xref>). Across all 3 domains, most of the studies were either local or national or involved multiple cities. Most of the treatment studies were from Europe (n = 64) and the United States (n = 33). In the treatment domain, we found 21 studies that included information related to both HAART for HIV and pegylated interferon and ribavirin treatment for HCV, 53 studies that investigated topics related only to HAART in co-infected people and 40 studies that investigated topics related only to pegylated interferon and ribavirin treatment in co-infected people. In the epidemiology domain, all of the 52 studies found included information related to epidemiologic trends of co-infection in key populations at high risk of HIV or HCV infection, or co-infection. Of these studies, 24 included current and former injection drug users, 8 included prison populations and 5 included people who had mental illness. In the care, support, programming and prevention domain, 43 studies addressed topics related to care, support and programming only, 5 addressed topics related to prevention only and 31 addressed both topics. More than half of the publications and reports in this domain addressed issues related to IDU. (A full list of the references found for each of the 3 domains is available at <ext-link ext-link-type="uri" xlink:href="http://www.ohtn.on.ca/Pages/Knowledge-Exchange/HIV-HCV-Scoping-Review.aspx">http://www.ohtn.on.ca/Pages/Knowledge-Exchange/HIV-HCV-Scoping-Review.aspx</ext-link>.)</p><fig id="figure1" position="float"><label>Figure 1</label><caption><p>Study selection</p></caption><graphic xlink:href="OpenMed-03-e184-g005"/></fig><fig id="table1" position="float"><label>Table 1</label><caption><p>Systematic reviews and treatment guidelines: quality assessment and study characteristics</p></caption><graphic xlink:href="OpenMed-03-e184-g006"/></fig></sec><sec><title>Discussion</title><p>Overall, we found that the literature on HIV&#x02013;HCV co-infection is fairly well defined. We identified 9 treatment guidelines and 10 systematic reviews that addressed 1 or more of the 3 topic domains, which provides those delivering treatment, care and support with a reliable evidence base to draw from. The quality-assessed inventory of treatment guidelines and systematic reviews can be used by physicians and service providers to rapidly determine whether there are guidelines or reviews available that are specific to their jurisdiction and of sufficient quality to help with decision-making about treatment or other service-delivery issues. </p><p>Although we found a number of treatment guidelines and systematic reviews, many were based on literature that did not include current injection drug users or people with mental health issues because of limited evidence from these populations (especially in the treatment literature). As a result, guidelines and reviews often indicate that treatment in these populations should proceed on a &#x0201c;case-by-case basis.&#x0201d; This finding is particularly salient given that the epidemiologic literature indicates that co-infection is mostly found among current and former injection drug users.<xref ref-type="bibr" rid="ref18">18</xref> Therefore, much of the evidence (particularly in the treatment literature) either is limited in its scope and applicability to important populations that are vulnerable to HIV or HCV infection or co-infection, or lacks detail about how to deliver treatment to these populations while ensuring appropriate supportive care. Because active drug use and mental illness can reduce access to, adherence to and effectiveness of treatment for both HIV and HCV infections, programs to improve the health of co-infected patients must include a multidisciplinary approach using specialists in HCV and HIV treatment for injection drug users and those with mental illness. </p><p>The main clinical trials for HCV treatment involving HIV&#x02013;HCV co-infected individuals used 800 mg per day of ribavirin.<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref> This is lower than the current standard of care and may have diminished the sustained virological response obtained in these studies. In these studies, infected participants with genotype 2 or 3 received 48 weeks of therapy. It is not clear whether shorter treatment durations are equally effective. Additional evaluation of alternative dosing strategies in HIV&#x02013;HCV co-infected populations is warranted. The HIV nucleosides used for HIV treatment in these early HCV studies (i.e., stavudine, didanosine, zidovudine) differ from those that are now used as part of standard practice. Each of these medications may have negative effects on overall tolerance of HCV therapy and sustained virological response. For example, combination didanosine&#x02013;ribavirin therapy is now contraindicated because of increased risk of pancreatitis.<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref56">56</xref> The co-administration of zidovudine with ribavirin is not advised because it may exacerbate HCV treatment-related anemia and treatment-related fatigue, and increase the need for dose reduction, thereby diminishing sustained virological response.<xref ref-type="bibr" rid="ref57">57</xref></p><p>In Canada, there are high levels of HIV&#x02013;HCV co-infection among populations at high risk of HIV and HCV infection, such as current and former injection drug users, people with mental health illness and current and former prisoners. Thus, there is an increasing need to integrate prevention, screening, care, support and programming efforts and the funding streams for existing programs. An integrated programming and funding strategy will allow for populations to receive services for care, support and prevention, not only for HIV&#x02013;HCV co-infection but also for other co-morbidities such as IDU and mental health issues. </p><p>The primary strengths of this scoping review are that it provides a rigorous systematic assessment of the literature on HIV&#x02013;HCV co-infection across 3 domains, an inventory of treatment guidelines and systematic reviews that have been assessed for quality, a clear sense of the populations that have been a focus in the co-infection literature, and a direction for future research initiatives.</p><p>Several limitations of our scoping review should be highlighted. First, we did not include all relevant databases, such as EMBASE and CINAHL, which may have captured additional relevant publications that may not be found in MEDLINE. These databases were omitted because we wanted to conduct a relatively rapid review of the literature. We are confident that we captured much of the relevant literature available. Second, the agreement between reviewers was only fair (Kappa statistics 0.377 and 0.249). This low agreement is likely attributable to the fact that many abstracts were difficult to assess using our broad inclusion criteria, especially in the treatment domain since it was often difficult to discern the exact treatment regimen without reviewing the full text. As a result, we were over-inclusive at the title- and abstract-review stage because we deemed it more important to ensure that we did not inadvertently exclude any relevant studies. Finally, because we wanted to focus on Canadian and other North American literature and to keep the review focused and rapid, we did not consider some important populations. Therefore, we excluded studies from developing countries and studies that focused only on people with hemophilia, deeming these to have different contexts that require separate analysis.</p><p>Our findings are not meant to be an exhaustive analysis of outcomes that would normally be found in a systematic review but rather are an outline of the primary themes that emerged from the systematic reviews, treatment guidelines, longitudinal studies and key references for care, support, programming and prevention that were included in this review. This outline of primary themes was prepared to provide a broad evidence base for the multi-stakeholder think tank that this scoping review was originally commissioned for. </p><p>Given the limited scope of some of the literature that we located, there is a need to expand co-infection research initiatives (particularly in the treatment and support domains) to injection drug users and mental health populations and to ensure that existing systematic reviews and treatment guidelines are updated as new data from these initiatives emerges. In addition, beyond the topics of methadone treatment and needle exchange for injection drug users, the literature about care, support, programming and prevention appears to lack enough depth for a full systematic review. Therefore, future research should attempt to evaluate or highlight integrated and interdisciplinary care models that use a harm-reduction approach for the treatment, care and support for people co-infected with HIV and HCV. Intervention research would help determine prevention efforts and support services for co-infected people and those at risk. Last, tracking the epidemiologic profile of HIV&#x02013;HCV co-infection needs to continue with rigorous longitudinal models.</p></sec></body><back><ack><p>This scoping review was commissioned to provide an evidence base that could be used to inform a think tank (Hepatitis C and HIV co-infection in Ontario: What we know, where we are, and how to move forward, held on April 16, 2007) that was co-sponsored by the AIDS Bureau and the Hepatitis C Secretariat of the Ontario Ministry of Health and Long-Term Care, the Canadian Treatment Action Council, and the Ontario HIV Treatment Network (OHTN). We thank the OHTN for its financial and staff support of this scoping review.</p></ack><fn-group><fn fn-type="conflict"><p>Competing interests: None declared.</p></fn><fn fn-type="financial-disclosure"><p>Funding source: This scoping review was funded by the Ontario HIV Treatment Network, which provided the staff support and office resources needed to conduct the review and prepare the manuscript.</p></fn><fn fn-type="con"><p>Contributors: Each of the authors contributed to developing the design and interpretation of the study. Michael Wilson, Melisa Dickie and Curtis Cooper conducted the data acquisition and analysis. Michael Wilson drafted the manuscript, with contributions from Melisa Dickie and Curtis Cooper in the introduction, results and discussion sections and with contributions from Adriana Carvalhal, Jean Bacon and Sean Rourke in the critical review of earlier drafts. All of the authors read and approved the final manuscript for publication.</p></fn></fn-group><app-group><title>Appendix</title><app id="appendix1"><label>Appendix 1</label><fig id="appendix1_fig" position="anchor"><caption><p>Systematic reviews and treatment guidelines: quality assessment and study characteristics</p></caption><graphic xlink:href="OpenMed-03-e184-s001"/></fig></app></app-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><collab>Canadian Public Health Association</collab><source>Leading together: Canada takes action on HIV/AIDS (2005&#x02013;2010)</source><year>2005</year><publisher-loc>Ottawa</publisher-loc><publisher-name>The Association</publisher-name></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogg</surname><given-names>R S</given-names></name><name><surname>Yip</surname><given-names>B</given-names></name><name><surname>Kully</surname><given-names>C</given-names></name><name><surname>Craib</surname><given-names>K J</given-names></name><name><surname>O'Shaughnessy</surname><given-names>M V</given-names></name><name><surname>Schechter</surname><given-names>M T</given-names></name><name><surname>Montaner</surname><given-names>J S</given-names></name></person-group><article-title>Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens</article-title><source>CMAJ</source><year>1999</year><volume>160</volume><issue>5</issue><fpage>659</fpage><lpage>665</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=10102000">http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=10102000</ext-link></comment><pub-id pub-id-type="pmid">10102000</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rusch</surname><given-names>Melanie</given-names></name><name><surname>Nixon</surname><given-names>Stephanie</given-names></name><name><surname>Schilder</surname><given-names>Arn</given-names></name><name><surname>Braitstein</surname><given-names>Paula</given-names></name><name><surname>Chan</surname><given-names>Keith</given-names></name><name><surname>Hogg</surname><given-names>Robert S</given-names></name></person-group><article-title>Prevalence of activity limitation among persons living with HIV/AIDS in British Columbia</article-title><source>Can J Public Health</source><year>2004</year><volume>95</volume><issue>6</issue><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">15622793</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rusch</surname><given-names>Melanie</given-names></name><name><surname>Nixon</surname><given-names>Stephanie</given-names></name><name><surname>Schilder</surname><given-names>Arn</given-names></name><name><surname>Braitstein</surname><given-names>Paula</given-names></name><name><surname>Chan</surname><given-names>Keith</given-names></name><name><surname>Hogg</surname><given-names>Robert S</given-names></name></person-group><article-title>Impairments, activity limitations and participation restrictions: prevalence and associations among persons living with HIV/AIDS in British Columbia</article-title><source>Health Qual Life Outcomes</source><year>2004</year><month>9</month><day>06</day><volume>2</volume><fpage>46</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.hqlo.com/content/2//46">http://www.hqlo.com/content/2//46</ext-link></comment><pub-id pub-id-type="doi">10.1186/1477-7525-2-46</pub-id><pub-id pub-id-type="pmid">15350202</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worthington</surname><given-names>Catherine</given-names></name><name><surname>Myers</surname><given-names>Ted</given-names></name><name><surname>O'Brien</surname><given-names>Kelly</given-names></name><name><surname>Nixon</surname><given-names>Stephanie</given-names></name><name><surname>Cockerill</surname><given-names>Rhonda</given-names></name></person-group><article-title>Rehabilitation in HIV/AIDS: development of an expanded conceptual framework</article-title><source>AIDS Patient Care STDS</source><year>2005</year><volume>19</volume><issue>4</issue><fpage>258</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1089/apc.2005.19.258</pub-id><pub-id pub-id-type="pmid">15857198</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Braitstein</surname><given-names>P</given-names></name></person-group><source>Roadmap for addressing the epidemic of HIV and hepatitis C co-infection in Canada: Issues, recommendations, priorities and next steps</source><year>2004</year><publisher-loc>Toronto</publisher-loc><publisher-name>Canadian Treatment Action Council</publisher-name></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>J</given-names></name><name><surname>Kaye</surname><given-names>M</given-names></name><name><surname>Skidmore</surname><given-names>S</given-names></name><name><surname>Pillay</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>D A</given-names></name><name><surname>Dore</surname><given-names>G J</given-names></name></person-group><article-title>HIV and hepatitis C coinfection within the CAESAR study</article-title><source>HIV Med</source><year>2004</year><volume>5</volume><issue>3</issue><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1293.2004.00207.x</pub-id><pub-id pub-id-type="pmid">15139984</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backus</surname><given-names>Lisa I</given-names></name><name><surname>Boothroyd</surname><given-names>Derek</given-names></name><name><surname>Deyton</surname><given-names>Lawrence R</given-names></name></person-group><article-title>HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations</article-title><source>AIDS</source><year>2005</year><volume>19</volume><issue>suppl 3</issue><fpage>S3</fpage><lpage>S13</lpage><pub-id pub-id-type="pmid">16251809</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffet-Janvresse</surname><given-names>Claudine</given-names></name><name><surname>Peigue-Lafeuille</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><name><surname>Benichou</surname><given-names>Jacques</given-names></name><name><surname>Vabret</surname><given-names>Astrid</given-names></name><name><surname>Branger</surname><given-names>Michel</given-names></name><name><surname>Trimoulet</surname><given-names>Pascale</given-names></name><name><surname>Goria</surname><given-names>Odile</given-names></name><name><surname>Laurichesse</surname><given-names>Henri</given-names></name><name><surname>Abbed</surname><given-names>Abdelaziz</given-names></name><name><surname>Verdon</surname><given-names>Renaud</given-names></name><name><surname>Bouvet</surname><given-names>Elisabeth</given-names></name><name><surname>Lafon</surname><given-names>Marie-Edith</given-names></name><name><surname>Dussaix</surname><given-names>Elisabeth</given-names></name><name><surname>Cormerais</surname><given-names>Louis</given-names></name><name><surname>Dupon</surname><given-names>Michel</given-names></name><name><surname>Henquell</surname><given-names>C&#x000e9;cile</given-names></name><name><surname>Josse</surname><given-names>Annie</given-names></name><name><surname>Lagoutte</surname><given-names>Philippe</given-names></name><name><surname>Lariven</surname><given-names>Sylvie</given-names></name><name><surname>LeGac</surname><given-names>Sylvie</given-names></name><name><surname>Riachi</surname><given-names>Ghassan</given-names></name><name><surname>Verdon</surname><given-names>Renault</given-names></name><name><surname>Vittecoq</surname><given-names>Didier</given-names></name></person-group><collab>HIV-HCV Cohort Study Group</collab><article-title>HIV and HCV co-infection: situation at six French university hospitals in the year 2000</article-title><source>J Med Virol</source><year>2003</year><volume>69</volume><issue>1</issue><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1002/jmv.10268</pub-id><pub-id pub-id-type="pmid">12436472</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huckans</surname><given-names>Marilyn S</given-names></name><name><surname>Blackwell</surname><given-names>Aaron D</given-names></name><name><surname>Harms</surname><given-names>Todd A</given-names></name><name><surname>Indest</surname><given-names>David W</given-names></name><name><surname>Hauser</surname><given-names>Peter</given-names></name></person-group><article-title>Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection</article-title><source>AIDS</source><year>2005</year><volume>19</volume><issue>Suppl 3</issue><fpage>S106</fpage><lpage>S115</lpage><pub-id pub-id-type="pmid">16251805</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>Cari L</given-names></name><name><surname>Wood</surname><given-names>Evan</given-names></name><name><surname>Spittal</surname><given-names>Patricia M</given-names></name><name><surname>Li</surname><given-names>Kathy</given-names></name><name><surname>Frankish</surname><given-names>James C</given-names></name><name><surname>Braitstein</surname><given-names>Paula</given-names></name><name><surname>Montaner</surname><given-names>Julio S G</given-names></name><name><surname>Schechter</surname><given-names>Martin T</given-names></name></person-group><article-title>The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users</article-title><source>J Acquir Immune Defic Syndr</source><year>2004</year><volume>36</volume><issue>2</issue><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">15167294</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>C L</given-names></name><name><surname>Spittal</surname><given-names>P M</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>K</given-names></name><name><surname>Schechter</surname><given-names>M T</given-names></name><name><surname>Montaner</surname><given-names>J S G</given-names></name><name><surname>Hogg</surname><given-names>R S</given-names></name></person-group><article-title>Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations</article-title><source>AIDS Care</source><year>2006</year><volume>18</volume><issue>8</issue><fpage>968</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/09540120500481480</pub-id><pub-id pub-id-type="pmid">17012087</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Millson</surname><given-names>P</given-names></name><name><surname>Leonard</surname><given-names>L</given-names></name><name><surname>Remis</surname><given-names>RS</given-names></name><name><surname>Strike</surname><given-names>C</given-names></name><name><surname>Challacombe</surname><given-names>L</given-names></name></person-group><source>Injection drug use, HIV and HCV infection in Ontario: The evidence 1992 to 2004</source><year>2004</year><publisher-loc>Toronto</publisher-loc><publisher-name>AIDS Bureau, Ontario Ministry of Health and Long-Term Care</publisher-name></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>D M</given-names></name><name><surname>Tyndall</surname><given-names>M W</given-names></name><name><surname>Cornelisse</surname><given-names>P G</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Sherlock</surname><given-names>C H</given-names></name><name><surname>Rekart</surname><given-names>M L</given-names></name><name><surname>Strathdee</surname><given-names>S A</given-names></name><name><surname>Currie</surname><given-names>S L</given-names></name><name><surname>Schechter</surname><given-names>M T</given-names></name><name><surname>O'Shaughnessy</surname><given-names>M V</given-names></name></person-group><article-title>Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection</article-title><source>CMAJ</source><year>2001</year><volume>165</volume><issue>7</issue><fpage>889</fpage><lpage>895</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=11599327">http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=11599327</ext-link></comment><pub-id pub-id-type="pmid">11599327</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Remis</surname><given-names>RS</given-names></name></person-group><source>Final report: estimating the number of persons co-infected with hepatitis C virus and human immunodeficiency virus in Canada</source><year>2001</year><publisher-loc>Ottawa</publisher-loc><publisher-name>Hepatitis C Division, Population and Public Health Branch, Health Canada</publisher-name></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Remis</surname><given-names>RS</given-names></name></person-group><source>The epidemiology of hepatitis C infection in Ontario</source><year>2004</year><publisher-loc>Toronto</publisher-loc><publisher-name>Hepatitis C Secretariat, Community Health Division, Ontario Ministry of Health and Long-Term Care</publisher-name></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tedaldi</surname><given-names>Ellen M</given-names></name><name><surname>Hullsiek</surname><given-names>Katherine Huppler</given-names></name><name><surname>Malvestutto</surname><given-names>Carlos D</given-names></name><name><surname>Arduino</surname><given-names>Roberto C</given-names></name><name><surname>Fisher</surname><given-names>Evelyn J</given-names></name><name><surname>Gaglio</surname><given-names>Paul J</given-names></name><name><surname>Jenny-Avital</surname><given-names>Elizabeth R</given-names></name><name><surname>McGowan</surname><given-names>Joseph P</given-names></name><name><surname>Perez</surname><given-names>George</given-names></name><name><surname>Terry</surname><given-names>Beirn Community Programs for Clinical Research on AIDS</given-names></name></person-group><article-title>Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS</article-title><source>Clin Infect Dis</source><year>2003</year><month>5</month><day>06</day><volume>36</volume><issue>10</issue><fpage>1313</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1086/374841</pub-id><pub-id pub-id-type="pmid">12746778</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="book"><collab>Health Public Agency of Canada</collab><source>HIV/AIDS Epi updates</source><year>2007</year><publisher-loc>Ottawa</publisher-loc><publisher-name>The Agency</publisher-name></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Dunning</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>M</given-names></name></person-group><article-title>HIV and hepatitis C co-infection</article-title><source>Int J Clin Pract</source><year>2005</year><volume>59</volume><issue>9</issue><fpage>1082</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2005.00596.x</pub-id><pub-id pub-id-type="pmid">16115185</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="book"><collab>Centers for Disease Control and Prevention</collab><source>Hepatitis C virus and HIV co-infection</source><year>2002</year><publisher-loc>Atlanta (GA)</publisher-loc><publisher-name>The Centers</publisher-name></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calzavara</surname><given-names>Liviana</given-names></name><name><surname>Ramuscak</surname><given-names>Nancy</given-names></name><name><surname>Burchell</surname><given-names>Ann N</given-names></name><name><surname>Swantee</surname><given-names>Carol</given-names></name><name><surname>Myers</surname><given-names>Ted</given-names></name><name><surname>Ford</surname><given-names>Peter</given-names></name><name><surname>Fearon</surname><given-names>Margaret</given-names></name><name><surname>Raymond</surname><given-names>Sue</given-names></name></person-group><article-title>Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities</article-title><source>CMAJ</source><year>2007</year><volume>177</volume><issue>3</issue><fpage>257</fpage><lpage>261</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=17664449">http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=17664449</ext-link></comment><pub-id pub-id-type="doi">10.1503/cmaj.060416</pub-id><pub-id pub-id-type="pmid">17664449</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulin</surname><given-names>C&#x000e9;line</given-names></name><name><surname>Alary</surname><given-names>Michel</given-names></name><name><surname>Lambert</surname><given-names>Gilles</given-names></name><name><surname>Godin</surname><given-names>Gaston</given-names></name><name><surname>Landry</surname><given-names>Suzanne</given-names></name><name><surname>Gagnon</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><name><surname>Demers</surname><given-names>Eric</given-names></name><name><surname>Morarescu</surname><given-names>Elena</given-names></name><name><surname>Rochefort</surname><given-names>Jean</given-names></name><name><surname>Claessens</surname><given-names>Christiane</given-names></name></person-group><article-title>Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons</article-title><source>CMAJ</source><year>2007</year><volume>177</volume><issue>3</issue><fpage>252</fpage><lpage>256</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=17664448">http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=17664448</ext-link></comment><pub-id pub-id-type="doi">10.1503/cmaj.060760</pub-id><pub-id pub-id-type="pmid">17664448</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landau</surname><given-names>A</given-names></name><name><surname>Batisse</surname><given-names>D</given-names></name><name><surname>Piketty</surname><given-names>C</given-names></name><name><surname>Duong Van Huyen</surname><given-names>J P</given-names></name><name><surname>Bloch</surname><given-names>F</given-names></name><name><surname>Belec</surname><given-names>L</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>L</given-names></name><name><surname>Jian</surname><given-names>R</given-names></name><name><surname>Kazatchkine</surname><given-names>M D</given-names></name></person-group><article-title>Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients</article-title><source>AIDS</source><year>2001</year><volume>15</volume><issue>16</issue><fpage>2149</fpage><lpage>2155</lpage><pub-id pub-id-type="pmid">11684934</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torriani</surname><given-names>Francesca J</given-names></name><name><surname>Rodriguez-Torres</surname><given-names>Maribel</given-names></name><name><surname>Rockstroh</surname><given-names>J&#x000fc;rgen K</given-names></name><name><surname>Lissen</surname><given-names>Eduardo</given-names></name><name><surname>Gonzalez-Garc&#x000ed;a</surname><given-names>Juan</given-names></name><name><surname>Lazzarin</surname><given-names>Adriano</given-names></name><name><surname>Carosi</surname><given-names>Giampiero</given-names></name><name><surname>Sasadeusz</surname><given-names>Joseph</given-names></name><name><surname>Katlama</surname><given-names>Christine</given-names></name><name><surname>Montaner</surname><given-names>Julio</given-names></name><name><surname>Sette</surname><given-names>Hoel</given-names></name><name><surname>Passe</surname><given-names>Sharon</given-names></name><name><surname>De Pamphilis</surname><given-names>Jean</given-names></name><name><surname>Duff</surname><given-names>Frank</given-names></name><name><surname>Schrenk</surname><given-names>Uschi Marion</given-names></name><name><surname>Dieterich</surname><given-names>Douglas T</given-names></name></person-group><collab>APRICOT Study Group</collab><article-title>Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>5</issue><fpage>438</fpage><lpage>450</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://content.nejm.org/cgi/pmidlookup?view=short&#x00026;pmid=15282351&#x00026;promo=ONFLNS19">http://content.nejm.org/cgi/pmidlookup?view=short&#x00026;pmid=15282351&#x00026;promo=ONFLNS19</ext-link></comment><pub-id pub-id-type="doi">10.1056/NEJMoa040842</pub-id><pub-id pub-id-type="pmid">15282351</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>Michael W</given-names></name><name><surname>Shiffman</surname><given-names>Mitchell L</given-names></name><name><surname>Reddy</surname><given-names>K Rajender</given-names></name><name><surname>Smith</surname><given-names>Coleman</given-names></name><name><surname>Marinos</surname><given-names>George</given-names></name><name><surname>Gon&#x000e7;ales</surname><given-names>Fernando L</given-names></name><name><surname>H&#x000e4;ussinger</surname><given-names>Dieter</given-names></name><name><surname>Diago</surname><given-names>Moises</given-names></name><name><surname>Carosi</surname><given-names>Giampiero</given-names></name><name><surname>Dhumeaux</surname><given-names>Daniel</given-names></name><name><surname>Craxi</surname><given-names>Antonio</given-names></name><name><surname>Lin</surname><given-names>Amy</given-names></name><name><surname>Hoffman</surname><given-names>Joseph</given-names></name><name><surname>Yu</surname><given-names>Jian</given-names></name></person-group><article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><issue>13</issue><fpage>975</fpage><lpage>982</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://content.nejm.org/cgi/pmidlookup?view=short&#x00026;pmid=12324553&#x00026;promo=ONFLNS19">http://content.nejm.org/cgi/pmidlookup?view=short&#x00026;pmid=12324553&#x00026;promo=ONFLNS19</ext-link></comment><pub-id pub-id-type="doi">10.1056/NEJMoa020047</pub-id><pub-id pub-id-type="pmid">12324553</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>M P</given-names></name><name><surname>McHutchison</surname><given-names>J G</given-names></name><name><surname>Gordon</surname><given-names>S C</given-names></name><name><surname>Rustgi</surname><given-names>V K</given-names></name><name><surname>Shiffman</surname><given-names>M</given-names></name><name><surname>Reindollar</surname><given-names>R</given-names></name><name><surname>Goodman</surname><given-names>Z D</given-names></name><name><surname>Koury</surname><given-names>K</given-names></name><name><surname>Ling</surname><given-names>M</given-names></name><name><surname>Albrecht</surname><given-names>J K</given-names></name></person-group><article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial</article-title><source>Lancet</source><year>2001</year><volume>358</volume><issue>9286</issue><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">11583749</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulkowski</surname><given-names>Mark S</given-names></name><name><surname>Thomas</surname><given-names>David L</given-names></name></person-group><article-title>Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness</article-title><source>AIDS</source><year>2005</year><volume>19</volume><issue>suppl 3</issue><fpage>S8</fpage><lpage>S12</lpage><pub-id pub-id-type="pmid">16251833</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>EL</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Isaacs</surname><given-names>K</given-names></name><name><surname>Naseer</surname><given-names>M</given-names></name><name><surname>Gertis</surname><given-names>P</given-names></name></person-group><collab>Manhattan HIV Brain Bank</collab><article-title>Neuropsychiatric impact of hepatitis C on advanced HIV</article-title><source>Neurology</source><year>2004</year><volume>62</volume><issue>6</issue><fpage>957</fpage><lpage>962</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=15037699">http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=15037699</ext-link></comment><pub-id pub-id-type="pmid">15037699</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>Morris</given-names></name><name><surname>Shafran</surname><given-names>Stephen</given-names></name><name><surname>Burak</surname><given-names>Kelly</given-names></name><name><surname>Doucette</surname><given-names>Karen</given-names></name><name><surname>Wong</surname><given-names>Winnie</given-names></name><name><surname>Girgrah</surname><given-names>Nigel</given-names></name><name><surname>Yoshida</surname><given-names>Eric</given-names></name><name><surname>Renner</surname><given-names>Eberhard</given-names></name><name><surname>Wong</surname><given-names>Philip</given-names></name><name><surname>Desch&#x000ea;nes</surname><given-names>Marc</given-names></name></person-group><article-title>Management of chronic hepatitis C: consensus guidelines</article-title><source>Can J Gastroenterol</source><year>2007</year><volume>21</volume><issue>suppl C</issue><fpage>25C</fpage><lpage>34C</lpage><pub-id pub-id-type="pmid">17568824</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>Charles L</given-names></name><name><surname>Broadwell</surname><given-names>Sherry D</given-names></name><name><surname>Borisov</surname><given-names>Andrey S</given-names></name><name><surname>Manatunga</surname><given-names>Amita K</given-names></name><name><surname>Capuron</surname><given-names>Lucile</given-names></name><name><surname>Woolwine</surname><given-names>Bobbi J</given-names></name><name><surname>Jacobson</surname><given-names>Ira M</given-names></name><name><surname>Nemeroff</surname><given-names>Charles B</given-names></name><name><surname>Miller</surname><given-names>Andrew H</given-names></name></person-group><article-title>Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C</article-title><source>Brain Behav Immun</source><year>2005</year><volume>19</volume><issue>1</issue><fpage>23</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2004.05.001</pub-id><pub-id pub-id-type="pmid">15581735</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arksey</surname><given-names>H</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>L</given-names></name></person-group><article-title>Scoping studies: towards a methodological framework</article-title><source>Int J Soc Res Methodol</source><year>2005</year><volume>8</volume><issue>1</issue><fpage>19</fpage><lpage>32</lpage></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mays</surname><given-names>N</given-names></name><name><surname>Roberts</surname><given-names>E</given-names></name><name><surname>Popay</surname><given-names>J</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fulop</surname><given-names>N</given-names></name><name><surname>Allen</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Black</surname><given-names>N</given-names></name></person-group><article-title>Synthesising research evidence</article-title><source>Studying the organisation and delivery of health services: research methods</source><year>2001</year><publisher-loc>New York</publisher-loc><publisher-name>Routledge</publisher-name><fpage>188</fpage><lpage>214</lpage></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxman</surname><given-names>Andrew D</given-names></name><name><surname>Sch&#x000fc;nemann</surname><given-names>Holger J</given-names></name><name><surname>Fretheim</surname><given-names>Atle</given-names></name></person-group><article-title>Improving the use of research evidence in guideline development: 8. Synthesis and presentation of evidence</article-title><source>Health Res Policy Syst</source><year>2006</year><month>12</month><day>05</day><volume>4</volume><issue>1</issue><fpage>20</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.health-policy-systems.com/content/4//20">http://www.health-policy-systems.com/content/4//20</ext-link></comment><pub-id pub-id-type="doi">10.1186/1478-4505-4-20</pub-id><pub-id pub-id-type="pmid">17147809</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shea</surname><given-names>Beverley J</given-names></name><name><surname>Grimshaw</surname><given-names>Jeremy M</given-names></name><name><surname>Wells</surname><given-names>George A</given-names></name><name><surname>Boers</surname><given-names>Maarten</given-names></name><name><surname>Andersson</surname><given-names>Neil</given-names></name><name><surname>Hamel</surname><given-names>Candyce</given-names></name><name><surname>Porter</surname><given-names>Ashley C</given-names></name><name><surname>Tugwell</surname><given-names>Peter</given-names></name><name><surname>Moher</surname><given-names>David</given-names></name><name><surname>Bouter</surname><given-names>Lex M</given-names></name></person-group><article-title>Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews</article-title><source>BMC Med Res Methodol</source><year>2007</year><month>2</month><day>15</day><volume>7</volume><issue>1</issue><fpage>10</fpage><lpage>16</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2288/7/10">http://www.biomedcentral.com/1471-2288/7/10</ext-link></comment><pub-id pub-id-type="doi">10.1186/1471-2288-7-10</pub-id><pub-id pub-id-type="pmid">17302989</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="book"><collab>Canadian Agency for Drugs and Technologies in Health</collab><source>Methods for development. Updated 2009</source><publisher-loc>Ottawa</publisher-loc><publisher-name>The Agency</publisher-name></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><collab>The AGREE Collaboration</collab><article-title>Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project</article-title><source>Qual Saf Health Care</source><year>2003</year><volume>12</volume><issue>1</issue><fpage>18</fpage><lpage>23</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://qhc.bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=12571340">http://qhc.bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=12571340</ext-link></comment><pub-id pub-id-type="pmid">12571340</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="other"><collab>The AGREE Collaboration</collab><source>Appraisal of guidelines for research &#x00026; evaluation: instrument training manual</source><year>2003</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.agreecollaboration.org/pdf/aitraining.pdf">http://www.agreecollaboration.org/pdf/aitraining.pdf</ext-link></comment></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><collab>Centers for Disease Control and Prevention</collab><article-title>Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America</article-title><source>Morbid Mortal Wkly Rep</source><year>2004</year><volume>53</volume><issue>RR-15</issue></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>M</given-names></name><name><surname>Bain</surname><given-names>V</given-names></name><name><surname>Villeneuve</surname><given-names>JP</given-names></name><name><surname>Myers</surname><given-names>RP</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Lowe</surname><given-names>C</given-names></name></person-group><source>Management of viral hepatitis: a Canadian consensus conference, 2003/2004</source><year>2004</year><publisher-loc>Ottawa</publisher-loc><publisher-name>Health Canada and Correctional Service Canada</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.hepatology.ca/cm/FileLib/consensus_English_Aug_04.pdf">http://www.hepatology.ca/cm/FileLib/consensus_English_Aug_04.pdf</ext-link></comment></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano</surname><given-names>V</given-names></name><name><surname>Puoti</surname><given-names>M</given-names></name><name><surname>Sulkowski</surname><given-names>M</given-names></name><name><surname>Mauss</surname><given-names>S</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><name><surname>Cargnel</surname><given-names>A</given-names></name><name><surname>Dieterich</surname><given-names>D</given-names></name><name><surname>Hatzakis</surname><given-names>A</given-names></name><name><surname>Rockstroh</surname><given-names>J</given-names></name></person-group><article-title>Care of patients with hepatitis C and HIV co-infection</article-title><source>AIDS</source><year>2004</year><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15090824</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strader</surname><given-names>Doris B</given-names></name><name><surname>Wright</surname><given-names>Teresa</given-names></name><name><surname>Thomas</surname><given-names>David L</given-names></name><name><surname>Seeff</surname><given-names>Leonard B</given-names></name></person-group><collab>American Association for the Study of Liver Diseases</collab><article-title>Diagnosis, management, and treatment of hepatitis C</article-title><source>Hepatology</source><year>2004</year><volume>39</volume><issue>4</issue><fpage>1147</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1002/hep.20119</pub-id><pub-id pub-id-type="pmid">15057920</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>Alfredo</given-names></name><name><surname>Clumeck</surname><given-names>Nathan</given-names></name><name><surname>Collins</surname><given-names>Simon</given-names></name><name><surname>Gerlich</surname><given-names>Wolfram</given-names></name><name><surname>Lundgren</surname><given-names>Jens</given-names></name><name><surname>Pal&#x000f9;</surname><given-names>Giorgio</given-names></name><name><surname>Reiss</surname><given-names>Peter</given-names></name><name><surname>Thiebaut</surname><given-names>Rodolphe</given-names></name><name><surname>Weiland</surname><given-names>Ola</given-names></name><name><surname>Yazdanpanah</surname><given-names>Yazdan</given-names></name><name><surname>Zeuzem</surname><given-names>Stefan</given-names></name></person-group><collab>ECC Jury</collab><article-title>Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients</article-title><source>J Hepatol</source><year>2005</year><volume>42</volume><issue>5</issue><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.03.003</pub-id><pub-id pub-id-type="pmid">15916745</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Boucher</surname><given-names>M</given-names></name><name><surname>Gruslin</surname><given-names>A</given-names></name></person-group><source>The reproductive care of women living with hepatitis C infection</source><year>2000</year><publisher-loc>Ottawa</publisher-loc><publisher-name>Society of Obstetricians and Gynaecologists of Canada</publisher-name></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>M</given-names></name><name><surname>Matthews</surname><given-names>G</given-names></name><name><surname>Brook</surname><given-names>M G</given-names></name><name><surname>Main</surname><given-names>J</given-names></name></person-group><collab>BHIVA Coinfection Guideline Committee</collab><collab>British HIV Association</collab><article-title>BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection</article-title><source>HIV Med</source><year>2005</year><volume>6</volume><issue>suppl 2</issue><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1293.2005.00300.x</pub-id><pub-id pub-id-type="pmid">16011539</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonucci</surname><given-names>G</given-names></name><name><surname>Antinori</surname><given-names>A</given-names></name><name><surname>Boumis</surname><given-names>E</given-names></name><name><surname>De Longis</surname><given-names>P</given-names></name><name><surname>Gentile</surname><given-names>M</given-names></name><name><surname>Girardi</surname><given-names>E</given-names></name><name><surname>Lauria</surname><given-names>F N</given-names></name><name><surname>Narciso</surname><given-names>P</given-names></name><name><surname>Noto</surname><given-names>P</given-names></name><name><surname>Palmieri</surname><given-names>F</given-names></name><name><surname>Oliva</surname><given-names>A</given-names></name><name><surname>Petrosillo</surname><given-names>N</given-names></name><name><surname>Rosati</surname><given-names>S</given-names></name><name><surname>Urso</surname><given-names>R</given-names></name><name><surname>Tocci</surname><given-names>G</given-names></name><name><surname>Tozzi</surname><given-names>V</given-names></name><name><surname>Visco</surname><given-names>Comandini U</given-names></name><name><surname>Ippolito</surname><given-names>G</given-names></name></person-group><article-title>Guidelines for the management of HCV infection in HIV-infected patients. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani</article-title><source>Infez Med</source><year>2004</year><volume>12</volume><issue>1</issue><fpage>7</fpage><lpage>18</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.infezmed.it/VisualizzaUnArticolo.aspx?Anno=2004&#x00026;numero=1&#x00026;ArticoloDaVisualizzare=Vol_12_1_2004_1">http://www.infezmed.it/VisualizzaUnArticolo.aspx?Anno=2004&#x00026;numero=1&#x00026;ArticoloDaVisualizzare=Vol_12_1_2004_1</ext-link></comment><pub-id pub-id-type="pmid">15329524</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>A I</given-names></name><name><surname>Dorn</surname><given-names>A</given-names></name><name><surname>Bouajram</surname><given-names>R</given-names></name><name><surname>Saab</surname><given-names>S</given-names></name></person-group><article-title>The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis</article-title><source>HIV Med</source><year>2007</year><volume>8</volume><issue>5</issue><fpage>312</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1293.2007.00476.x</pub-id><pub-id pub-id-type="pmid">17561878</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohsen</surname><given-names>A H</given-names></name><name><surname>Easterbrook</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>C B</given-names></name><name><surname>Norris</surname><given-names>S</given-names></name></person-group><article-title>Hepatitis C and HIV-1 coinfection</article-title><source>Gut</source><year>2002</year><volume>51</volume><issue>4</issue><fpage>601</fpage><lpage>608</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://gut.bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=12235089">http://gut.bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=12235089</ext-link></comment><pub-id pub-id-type="pmid">12235089</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Brodin</surname><given-names>H</given-names></name><name><surname>Cave</surname><given-names>C</given-names></name><name><surname>Waugh</surname><given-names>N</given-names></name><name><surname>Price</surname><given-names>A</given-names></name><name><surname>Gabbay</surname><given-names>J</given-names></name></person-group><article-title>Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation</article-title><source>Health Technol Assess (Rockv)</source><year>2004</year><volume>8</volume><issue>39</issue><fpage>1</fpage><lpage>140</lpage></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gebo</surname><given-names>Kelly A</given-names></name><name><surname>Jenckes</surname><given-names>Mollie W</given-names></name><name><surname>Chander</surname><given-names>Geetanjali</given-names></name><name><surname>Torbenson</surname><given-names>Michael S</given-names></name><name><surname>Ghanem</surname><given-names>Khalil G</given-names></name><name><surname>Herlong</surname><given-names>H Franklin</given-names></name><name><surname>Sulkowski</surname><given-names>Mark S</given-names></name><name><surname>El-Kamary</surname><given-names>Samer S</given-names></name><name><surname>Harris</surname><given-names>Kirk A</given-names></name><name><surname>Guedelhoefer</surname><given-names>Otto C</given-names></name><name><surname>Bass</surname><given-names>Eric B</given-names></name></person-group><source>Management of chronic hepatitis C</source><year>2002</year><publisher-loc>Rockville (MD)</publisher-loc><publisher-name>Agency for Healthcare Research and Quality</publisher-name></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>C S</given-names></name><name><surname>Baden</surname><given-names>L R</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Mrus</surname><given-names>J M</given-names></name><name><surname>Carnie</surname><given-names>J</given-names></name><name><surname>Heeren</surname><given-names>T</given-names></name><name><surname>Koziel</surname><given-names>M J</given-names></name></person-group><article-title>Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis</article-title><source>Clin Infect Dis</source><year>2001</year><month>7</month><day>06</day><volume>33</volume><issue>4</issue><fpage>562</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1086/321909</pub-id><pub-id pub-id-type="pmid">11462196</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faggiano</surname><given-names>F</given-names></name><name><surname>Vigna-Taglianti</surname><given-names>F</given-names></name><name><surname>Versino</surname><given-names>E</given-names></name><name><surname>Lemma</surname><given-names>P</given-names></name></person-group><article-title>Methadone maintenance at different dosages for opioid dependence</article-title><source>Cochrane Database Syst Rev</source><year>2003</year><issue>3</issue><fpage>CD002208</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD002208</pub-id><pub-id pub-id-type="pmid">12917925</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>L</given-names></name><name><surname>Forrester</surname><given-names>L</given-names></name><name><surname>Navarro</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Doucet</surname><given-names>C</given-names></name></person-group><source>The effectiveness of needle exchange programs in modifying HIV-related outcomes: A systematic review of the evidence 1997&#x02013;1999</source><year>1999</year><publisher-loc>Hamilton (ON)</publisher-loc><publisher-name>Effective Public Health Practice Project</publisher-name></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connor</surname><given-names>AM</given-names></name><name><surname>Stacey</surname><given-names>D</given-names></name><name><surname>Entwistle</surname><given-names>V</given-names></name><name><surname>Llewellyn</surname><given-names>TH</given-names></name><name><surname>Rovner</surname><given-names>D</given-names></name><name><surname>Holmes</surname><given-names>RM</given-names></name><name><surname>Tait</surname><given-names>V</given-names></name><name><surname>Tetroe</surname><given-names>J</given-names></name></person-group><article-title>Decision aids for people facing health treatment or screening decisions</article-title><source>Cochrane Database Syst Rev</source><year>2003</year><issue>1</issue><fpage>CD001431</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD001431</pub-id><pub-id pub-id-type="pmid">12804407</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>L</given-names></name><name><surname>Davoli</surname><given-names>M</given-names></name><name><surname>Minozzi</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name><name><surname>Ferri</surname><given-names>M</given-names></name></person-group><article-title>Methadone at tapered doses for the management of opioid withdrawal</article-title><source>Cochrane Database Syst Rev</source><year>2005</year><month>7</month><day>20</day><issue>3</issue><fpage>CD003409</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD003409.pub3</pub-id><pub-id pub-id-type="pmid">16034898</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowing</surname><given-names>L</given-names></name><name><surname>Farrell</surname><given-names>M</given-names></name><name><surname>Bornemann</surname><given-names>R</given-names></name><name><surname>Sullivan</surname><given-names>L</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name></person-group><article-title>Substitution treatment of injecting opioid users for prevention of HIV infection</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><month>4</month><day>16</day><issue>2</issue><fpage>CD004145</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD004145.pub3</pub-id><pub-id pub-id-type="pmid">18425898</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafeuillade</surname><given-names>A</given-names></name><name><surname>Hittinger</surname><given-names>G</given-names></name><name><surname>Chadapaud</surname><given-names>S</given-names></name></person-group><article-title>Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection</article-title><source>Lancet</source><year>2001</year><volume>357</volume><issue>9252</issue><fpage>280</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)03618-7</pub-id><pub-id pub-id-type="pmid">11214134</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bani-Sadr</surname><given-names>F</given-names></name><name><surname>Goderel</surname><given-names>I</given-names></name><name><surname>Penalba</surname><given-names>C</given-names></name><name><surname>Billaud</surname><given-names>E</given-names></name><name><surname>Doll</surname><given-names>J</given-names></name><name><surname>Welker</surname><given-names>Y</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><name><surname>Pol</surname><given-names>S</given-names></name><name><surname>Perronne</surname><given-names>C</given-names></name><name><surname>Carrat</surname><given-names>F</given-names></name></person-group><collab>ANRS HC02 - Ribavic Study team</collab><article-title>Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin</article-title><source>J Viral Hepat</source><year>2007</year><volume>14</volume><issue>9</issue><fpage>639</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2007.00846.x</pub-id><pub-id pub-id-type="pmid">17697016</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowing</surname><given-names>L</given-names></name><name><surname>Farrell</surname><given-names>M</given-names></name><name><surname>Bornemann</surname><given-names>R</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name></person-group><article-title>Substitution treatment of injecting opioid users for prevention of HIV infection</article-title><source>Cochrane Database Syst Rev</source><year>2004</year><month>10</month><day>18</day><issue>4</issue><pub-id pub-id-type="doi">10.1002/14651858.CD004145.pub2</pub-id><pub-id pub-id-type="pmid">15495080</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>Christine A</given-names></name><name><surname>Shafran</surname><given-names>Stephen D</given-names></name></person-group><article-title>Treatment of hepatitis C in HIV-coinfected patients</article-title><source>Ann Pharmacother</source><year>2006</year><month>2</month><day>28</day><volume>40</volume><issue>3</issue><publisher-name>Ann Pharmacother</publisher-name><fpage>479</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1345/aph.1G427</pub-id><pub-id pub-id-type="pmid">16507622</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>C</given-names></name></person-group><article-title>Responding to HCV/HIV co-infection</article-title><source>Canadian Treatment Action Council Newsletter</source><year>2007</year><volume>9</volume><issue>1</issue></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>Glenn J</given-names></name><name><surname>Ryan</surname><given-names>Gery W</given-names></name></person-group><article-title>Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness</article-title><source>AIDS</source><year>2005</year><volume>19</volume><issue>suppl 3</issue><fpage>S190</fpage><lpage>S198</lpage><pub-id pub-id-type="pmid">16251817</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>Rainer</given-names></name><name><surname>Sabin</surname><given-names>Caroline A</given-names></name><name><surname>Friis-M&#x000f8;ller</surname><given-names>Nina</given-names></name><name><surname>Reiss</surname><given-names>Peter</given-names></name><name><surname>El-Sadr</surname><given-names>Wafaa M</given-names></name><name><surname>Kirk</surname><given-names>Ole</given-names></name><name><surname>Dabis</surname><given-names>Francois</given-names></name><name><surname>Law</surname><given-names>Matthew G</given-names></name><name><surname>Pradier</surname><given-names>Christian</given-names></name><name><surname>De Wit</surname><given-names>Stephane</given-names></name><name><surname>Akerlund</surname><given-names>B&#x000f6;rje</given-names></name><name><surname>Calvo</surname><given-names>Gonzalo</given-names></name><name><surname>Monforte</surname><given-names>Antonella d'Arminio</given-names></name><name><surname>Rickenbach</surname><given-names>Martin</given-names></name><name><surname>Ledergerber</surname><given-names>Bruno</given-names></name><name><surname>Phillips</surname><given-names>Andrew N</given-names></name><name><surname>Lundgren</surname><given-names>Jens D</given-names></name></person-group><article-title>Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><issue>15</issue><fpage>1632</fpage><lpage>1641</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://archinte.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=16908797">http://archinte.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=16908797</ext-link></comment><pub-id pub-id-type="doi">10.1001/archinte.166.15.1632</pub-id><pub-id pub-id-type="pmid">16908797</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinbaum</surname><given-names>Cindy M</given-names></name><name><surname>Sabin</surname><given-names>Keith M</given-names></name><name><surname>Santibanez</surname><given-names>Scott S</given-names></name></person-group><article-title>Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention</article-title><source>AIDS</source><year>2005</year><volume>19</volume><issue>suppl 3</issue><fpage>S41</fpage><lpage>S46</lpage><pub-id pub-id-type="pmid">16251827</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>S D</given-names></name><name><surname>Goodman</surname><given-names>L A</given-names></name><name><surname>Osher</surname><given-names>F C</given-names></name><name><surname>Swartz</surname><given-names>M S</given-names></name><name><surname>Essock</surname><given-names>S M</given-names></name><name><surname>Butterfield</surname><given-names>M I</given-names></name><name><surname>Constantine</surname><given-names>N T</given-names></name><name><surname>Wolford</surname><given-names>G L</given-names></name><name><surname>Salyers</surname><given-names>M P</given-names></name></person-group><article-title>Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness</article-title><source>Am J Public Health</source><year>2001</year><volume>91</volume><issue>1</issue><fpage>31</fpage><lpage>37</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=11189820">http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=11189820</ext-link></comment><pub-id pub-id-type="pmid">11189820</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>D</given-names></name><name><surname>Thomson</surname><given-names>K</given-names></name></person-group><source>A national hepatitis C strategy in Canada: A discussion paper</source><year>2004</year><publisher-loc>Ottawa (ON)</publisher-loc><publisher-name>Canadian AIDS Society</publisher-name></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rick</surname><given-names>Lines</given-names></name></person-group><source>Action on Hiv/aids in prisons: too Little, too Late - a report card</source><year>2002</year><publisher-loc>Montr&#x000e9;al</publisher-loc><publisher-name>Canadian HIV/AIDS Legal Network</publisher-name></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>Randy</given-names></name><name><surname>Reimer</surname><given-names>Gwen</given-names></name></person-group><source>Canadian Aboriginal people living with HIV/AIDS: care, treatment and support issues</source><year>2008</year><publisher-loc>Ottawa (ON)</publisher-loc><publisher-name>Canadian Aboriginal AIDS Network</publisher-name></element-citation></ref></ref-list></back></article>